Sugi Predict

Sugi Predict / Targets / HCAR2

HCAR2

Hydroxycarboxylic acid receptor 2 · Q8TDS4 · HCAR2 on Sugi Atlas →

120,679 patent compounds predicted against HCAR2, 69,733 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL26820 SCHEMBL26820 0.50 15/20
SCHEMBL70577 SCHEMBL70577 0.59 13/20
SCHEMBL30268 SCHEMBL30268 0.59 13/20
SCHEMBL39643 SCHEMBL39643 0.56 12/20
SCHEMBL39644 SCHEMBL39644 0.56 12/20
SCHEMBL63810 SCHEMBL63810 0.60 11/20
Ethyl Fumarate Ethyl Fumarate (SCHEMBL60568) 1.00 9/20
Ethyl Fumarate Ethyl Fumarate (SCHEMBL60569) 1.00 9/20
SCHEMBL99615 SCHEMBL99615 0.50 9/20
SCHEMBL99701 SCHEMBL99701 0.50 9/20
Butyl Fumarate Butyl Fumarate (SCHEMBL43164) 1.00 8/20
Butyl Fumarate Butyl Fumarate (SCHEMBL43165) 1.00 8/20
Bixin Bixin (SCHEMBL42729) 0.63 8/20
SCHEMBL87888 SCHEMBL87888 0.52 8/20
SCHEMBL33469 SCHEMBL33469 0.50 8/20
SCHEMBL70360 SCHEMBL70360 0.48 8/20
SCHEMBL101142 SCHEMBL101142 0.51 7/20
SCHEMBL51830 SCHEMBL51830 0.70 6/20
SCHEMBL78104 SCHEMBL78104 0.65 6/20
SCHEMBL40331 SCHEMBL40331 0.57 6/20

Clinical trials — most relevant to HCAR2 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Early Viscosupplementation After ACL Reconstruction: a Randomized Controlled Trial PHASE4COMPLETED
Ramatroban/Montelukast Versus Montelukast/Placebo on the Early Allergic Reaction in Asthma Sensitive to House Dust Mite PHASE2/PHASE3WITHDRAWN
Efficacy and Safety Study of Azilsartan Medoxomil Compared to Ramipril for Treating Essential Hypertension PHASE3COMPLETED
A Series of Pilot Studies to Evaluate the haemoDynamic and mEtabolic Effects oF apelIn aNd rElaxin PHASE2UNKNOWN
Role of the Gut Sweet Taste Receptor in the Secretion of Glucagon-like Peptide-1 and Peptide YY PHASE1COMPLETED
Sweet Taste Receptors and the Secretion of Glucagon-like Peptide-1 and Peptide YY PHASE1COMPLETED
FFAR Agonist on Incretins, Insulin, Lipids and Inflammation nanCOMPLETED
Dose-response Effect of Pine Nut Oil as a Dual FFA1 and FFA4 Agonist on Glucose Tolerance in Healthy Humans. nanCOMPLETED
Oat Bran and Plasma Lipid and Fecal Bacteria in Coronary Artery Disease Patients nanCOMPLETED
Effect of Dietary Oils as G-protein-coupled Receptor Agonists on Glucose Tolerance nanUNKNOWN
Gut Microbiome Analysis in Organ Transplant Recipient nanNOT_YET_RECRUITING
RCT to Describe the Effects of Colon Delivered Acetate, Propionate and Butyrate on Satiety and Glucose Homeostasis nanCOMPLETED
Investigating Optimal Propionate Delivery to the Colon Using Stable Isotope Labeling nanCOMPLETED
Gut Microbiota and Multiple Sclerosis nanUNKNOWN
GABRA2 and the Pharmacokinetics of Risk for Alcoholism (GPRA) nanCOMPLETED
Involvement of Pollutants in Atopic Dermatitis and Psoriasis nanUNKNOWN
Molecular Evaluation of TAAR1 and JAK/STAT Pathway in Hidradenitis Suppurativa nanCOMPLETED
Effects of Probiotics on Gut Microbiota, Endocannabinoid and Immune Activation and Symptoms of Fatigue in Dancers nanCOMPLETED
Forced Oscillometry in Infants With Bronchopulmonary Dysplasia nanRECRUITING
Inflammation Impact on Pain in Knee Osteoarthritis nanCOMPLETED
An Assessment of Cognitive Function in Irritable Bowel Syndrome nanUNKNOWN
Early Life Malnutrition, Environmental Enteric Dysfunction and Microbiome Trajectories nanRECRUITING
Searching for Novel Therapeutic Approaches in Migraine Patients Resistant to Treatments nanRECRUITING
The Severe Asthma Research Program III-Boston Clinical Site nanCOMPLETED
Brain Receptors in Sympathetic Nervous System Regulation nanCOMPLETED
In Vivo Assessment of Histamine Pharmacodynamics nanWITHDRAWN
Neutrophil FFA2/GPR43 Receptor Expression in Patients With the Diagnosis of Sepsis nanWITHDRAWN
Genetic Determinants of Cardiovascular Response to Coffee Drinking nanCOMPLETED
Observational Study of the Impact of Genetic Testing on Healthcare Decisions and Care in Interventional Pain Management nanUNKNOWN
Characterizing a 5P-Linked BHR Susceptibility Locus nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a HCAR2 binder may also engage these)

ProteinNameSimilarity
Q80Z39 — 1.000 Q80Z39 →
Q9EP66 — 1.000 Q9EP66 →
Q8C131 — 0.997 Q8C131 →
HCAR3 Hydroxycarboxylic acid receptor 3 0.995 landscape →
HCAR1 Hydroxycarboxylic acid receptor 1 0.992 landscape →
Q3U507 — 0.986 Q3U507 →
GPR174 Probable G-protein coupled receptor 174 0.986 landscape →
Q8BLG2 — 0.984 Q8BLG2 →
Q9XSD4 — 0.982 Q9XSD4 →
Q9Z282 — 0.982 Q9Z282 →
B0UXR0 — 0.982 B0UXR0 →
P2RY10 Putative P2Y purinoceptor 10 0.982 landscape →
GPR132 Probable G-protein coupled receptor 132 0.981 landscape →
CYSLTR2 Cysteinyl leukotriene receptor 2 0.981 landscape →
Q61038 — 0.980 Q61038 →
D4A7K7 — 0.980 D4A7K7 →
E7FEL0 — 0.980 E7FEL0 →
LPAR4 Lysophosphatidic acid receptor 4 0.979 landscape →
GPR55 G-protein coupled receptor 55 0.979 landscape →
Q3UJF0 — 0.979 Q3UJF0 →
Q3U6B2 — 0.978 Q3U6B2 →
D4A4Q2 — 0.978 D4A4Q2 →
Q9GK76 — 0.978 Q9GK76 →
P30558 — 0.977 P30558 →
B5X337 — 0.977 B5X337 →
Q924T8 — 0.977 Q924T8 →
P48042 — 0.977 P48042 →
P21556 — 0.976 P21556 →
GPR183 G-protein coupled receptor 183 0.976 landscape →
Q9TTY5 — 0.976 Q9TTY5 →